The trajectory of companies tied to Sildenafil's legacy presents a intricate investment picture . While the initial surge generated substantial gains, generic copies have significantly diminished market share . Investing in connected pharmaceutical companies now requires a thorough assessment of intellectual property rights , evolving medical chang